CS/BSE/NSE/PR/2016-2017

July 25, 2016

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai 400 051

To
The General Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

Stock Code: SUVEN - EQ

Stock Code: 530239

Dear Sir/Madam,
Sub: Press Release
With reference to above subject, please find enclosed Press Release of our
company titled Suven to Present at Alzheimer's Association International
Conference (AAIC)
This is for your information and records
Thanking You,
Yours faithfully,
For Suven Life Sciences Limited
K. Hanumantha Rao
Company Secretary

Suven Life Sciences Limited

Registered Office: 8-2-334 I SDE Serene Chambers I 6th Floor Road No.5 I Avenue 7
Banjara Hills I Hyderabad 500 034 I Telangana I India I CIN : L 24 1 10 T G 1989 P L C0 09 7 13
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com

News Release

Suven to Present at Alzheimer's Association International Conference (AAIC)

HYDERABAD, INDIA (July 25, 2016) Suven is exhibiting and presenting several exciting new
results and data presentations from Suvens portfolio of investigational neuroscience New
Chemical Entities (NCEs) are being presented at Alzheimer's Association International
Conference (AAIC) being held in Toronto, Canada during July 24th to 28th, 2016.
AAIC is the world's largest conference of its kind, where thousands of international
investigators, clinicians, researchers and care providers will gather to share the latest study
results, theories and discoveries bringing the world closer to breakthroughs in dementia
science.

Alzheimers disease is one of the scourges of modern day health care. Alzheimers is not just a
memory loss as everyone thinks but Alzheimers kills. Current Alzheimer's treatments cannot
stop Alzheimer's from progressing, they can temporarily slow the worsening of dementia
symptoms and improve quality of life Today, there is a worldwide effort under way to find
better ways to treat the disease, delay its onset, and prevent it from developing and this is
where Suven is focusing in developing a drug for the treatment of this debilitating disease.
Suven has excellent portfolio of new molecules through four mechanisms of action using 5HT6, 5-HT4, H3 and Neuronal Nicotinic acetylcholine receptors for the symptomatic treatment
of cognitive impairment in Alzheimers disease but also possibly useful in reducing the disease
progression. Suven scientists are presenting pre-clinical and clinical data on these molecule and
other NCEs on memory related disorders and major depressive disorder.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and

commercializing novel pharmaceutical products, which are first in class or best in class CNS
therapies through the use of GPCR targets. Suven has 3 clinical stage compounds, a Phase 2
undergoing candidate SUVN-502, Phase 1 completed candidate SUVN-G3031 and Phase 1
undergoing candidate SUVN-D4010 for Alzheimers disease and Schizophrenia. In addition to
that the Company has ten (10) internally-discovered therapeutic drug candidates currently in
pre-clinical stage of development targeting conditions such as ADHD, dementia, depression,
Huntingtons disease, Parkinsons disease and pain.
For more information please visit our Web site at http://www.suven.com

Risk Statement:
Except for historical information, all of the statements, expectations and assumptions, including
expectations and assumptions, contained in this news release may be forward-looking statements that
involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these
forward-looking statements, it is possible that future circumstances might differ from the assumptions on
which such statements are based. Other important factors which could cause results to differ materially
including outsourcing trends, economic conditions, dependence on collaborative partnership programs,
retention of key personnel, technological advances and continued success in growth of sales that may make
our products/services offerings less competitive; Suven may not undertake to update any forward-looking
statements that may be made from time to time.

Suven Life Sciences Limited

Registered Office: 8-2-334 I SDE Serene Chambers I 6th FloorRoad No.5 I Avenue 7
Banjara Hills I Hyderabad 500 034 I Telangana I India I C IN : L 24 110 T G19 89 PL C00 9 7 1 3
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com